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Abstract Ulcerative colitis (UC) is a chronic inflammatory
bowel disease characterized by periods of remission and
periods of relapse. Patients often present with symptoms such
as rectal bleeding, diarrhea and weight loss, and may require
hospitalization and evencolectomy.Long-termcomplications
ofUC includedecreasedquality of life andproductivity and an
increased risk of colorectal cancer.Mucosal healing (MH) has
gained progressive importance in the management of UC
patients. In this article, we review the endoscopic findings that
define both mucosal injury and MH, and the strengths and
limitations of the scoring systems currently available in clin-
ical practice. The basicmechanisms behind colonic injury and
MH are covered, highlighting the pathways through which
different drugs exert their effect towards reducing inflamma-
tion and promoting epithelial repair. A comprehensive review
of the evidence for approved drugs for UC to achieve and
maintain MH is provided, including a section on the phar-
macokinetics of anti-tumor necrosis factor (TNF)-a drugs.
Currently approved drugs with proven efficacy in achieving
MH in UC include salicylates, corticosteroids (induction
only), calcineurin inhibitors (induction only), thiopurines,
vedolizumab and anti-TNFa drugs (infliximab, adalimumab,
and golimumab). MH is of crucial relevance in the outcomes
of UC, resulting in lower incidences of clinical relapse, the
need for hospitalization and surgery, as well as reduced rates
of dysplasia and colorectal cancer. Finally, we present recent
evidence towards the need for a more strict definition of
completeMH as the preferred endpoint for UC patients, using
a combination of both endoscopic and histological findings.
Key Points
Mucosal healing (MH) is currently considered a
crucial endpoint in the management of ulcerative
colitis patients.
Through strikingly different pathways and
mechanisms, most drugs currently approved for UC
are able to both induce and maintain MH in the
majority of patients, but anti-tumor necrosis factor-a
agents have shown superior results in moderate to
severe disease.
Recent evidence highlights the importance of
complete MH, corresponding to normal mucosa
during endoscopic examination, when aiming for
improved outcomes in UC.
1 Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel
disease (IBD), first named in 1859 by Samuel Wilks [1].
More than 150 years later, its origin is still unknown, and
most likely results from the interaction between various
genetic and environmental factors [2]. It is currently
defined by a continuous mucosal inflammation of the
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rectum and a variable extent of the colon, without granu-
lomas on mucosal biopsies [1].
UC is a lifelong disease, characterized by periods of
remission and periods of relapse—the latter, often pre-
senting with a combination of diarrhea, rectal bleeding,
abdominal pain, malaise and weight loss, is responsible for
the overwhelming majority of the disease burden and
diminished quality of life [3, 4]. Patients newly diagnosed
with UC have a 5-year risk of colectomy of 10–35% [5],
and ultimately, persistent and extensive inflammatory
activity increases the long-term risk of colorectal cancer
[5].
In the past, disease management was aimed at control-
ling symptoms, such as rectal bleeding and increased fre-
quency of bowel movements [3]. Symptom assessment
remains an important facet of UC approach because it is
easily employed in the clinical setting [4], is widely
accepted by patients and physicians alike, and is still the
decisive factor when considering the severity of the dis-
ease, requirement for hospital admission, and indication for
surgery [3]. The adoption of standardized clinical scores,
such as the Truelove and Witts criteria [6] and the Mayo
score [7], allowed for a more objective assessment of the
disease, and, while these are often used in clinical trials
[8, 9], they are not yet validated.
This approach, directed at controlling and mitigating the
consequences of inflammation, did not target the inflam-
matory activity itself. Some evidence exists that the cor-
relation between symptoms and endoscopic findings in UC
is better than for Crohn’s disease (CD), with authors
reporting a good correlation between endoscopy and stool
frequency, and particularly rectal bleeding, of up to 0.76
(95% confidence interval [CI] 0.72–0.80] and 0.82 (95%
CI 0.78–0.85), respectively. Notwithstanding, there is an
imperfect correlation between symptoms and bowel
inflammation [10], and more than half of all patients in
clinical remission exhibit mucosal inflammation on endo-
scopy [11]. Conversely, there is a significant overlap
between the clinical presentation of IBD and other condi-
tions, such as irritable bowel syndrome (IBS) or infectious
diarrhea [4], and some authors have reported UC patients
on long-standing remission to present with IBS-like
symptoms (abdominal pain, increased stool frequency) two
to three times more often than controls [12], while others
found increased stool frequency in up to 27% of patients
with complete endoscopic and histological healing, sug-
gesting a possible role of non-inflammatory functional
bowel damage [13]. Finally, clinical remission while
receiving placebo reached up to 15% in a systematic
review of clinical trials [14], but there is mounting evi-
dence that achieving clinical remission without mucosal
healing (MH) does not associate with reduced rates of
hospitalization or colectomy over the years [15, 16].
Other attractive options to monitor UC patients include
the use of inflammatory markers, such as the serum
markers C-reactive protein and erythrocyte sedimentation
rate and the fecal marker calprotectin. The correlation
between endoscopic activity and serum inflammatory
markers is insufficient to warrant its broad use in UC [17];
for calprotectin, despite promising results [18–20], more
studies are needed to clarify adequate surveillance strate-
gies and cut-off levels before its broad implementation in
clinical practice.
Mucosal inflammation is a key component of both UC
and CD, but, unlike Crohn’s disease, a transmural disease
with both stricturing and penetrating phenotypes, disease
activity is limited to the mucosa in UC [1, 2]. It is therefore
no surprise that MH should prove an attractive target when
approaching UC patients, regardless of the disease extent,
inflammatory biomarkers, or clinical presentation. In the
past decade, extensive evidence has been published advo-
cating the importance of histological healing [21, 22] as it
demonstrated excellent correlation with reduced risk of
relapse [23] and hospitalization [24]. Some authors are now
suggesting that histological healing could be included in
the definition of MH in addition to the endoscopic findings
[25].
Current treatment options for UC include aminosalicy-
lates, such as sulfasalazine and mesalamine (5-aminosali-
cylic acid; 5-ASA) in both oral and rectal formulations,
corticosteroids (including systemic corticosteroids such as
prednisolone or hydrocortisone, and topical corticosteroids
such as budesonide), thiopurines (azathioprine and 6-mer-
captopurine), methotrexate, calcineurin inhibitors (ci-
closporine and tacrolimus), anti-tumor necrosis factor
(TNF)-a drugs (including infliximab, adalimumab, and
golimumab), and, more recently, the anti-integrin drug
vedolizumab [3, 26].
In this review, we aimed to provide an overview of the
mechanisms involved in the balance of continuous
mucosal injury and mucosal repair in UC, as well as the
pathways through which different drug classes act upon
the colonic mucosa towards reducing inflammation and
promoting cell repair. Moreover, we aimed to cover the
efficacy of the currently approved drugs for UC in
achieving MH, and, ultimately, how MH impacts the
course of the disease.
We performed a systematic search in the PubMed and
Cochrane Library Central databases in order to identify
relevant literature (the initial search was conducted in April
2016, and the final search was conducted in August 2016).
No restrictions were applied to language or publication
date. Keywords used included ‘inflammatory bowel dis-
ease’, ‘ulcerative colitis’, ‘mucosal healing’, ‘endoscopic
healing’, and ‘remission’. References of included articles
were also searched.
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2 Physiology and Pathology of Bowel
Inflammation
2.1 Mechanisms Involved in Mucosal Injury
In order to fully grasp the scope of the importance of MH,
as well as the mechanisms behind the therapeutic approach
to UC, comprehending the physiopathological response
involved in mucosal injury is required. An obvious concept
of mucosal injury relates to visible lesions during endo-
scopy [1], but before ulcers and erosions become macro-
scopically apparent, several biochemical pathways are
involved, including gap junction disruption at a molecular
level, increased epithelial permeability, cellular apoptosis,
mucosal infiltration of activated inflammatory and lym-
phocytic cells, villous and crypt architectural changes, and
destruction [27]. This cascade is most likely initiated when
a combination of bacterial, alimentary, and endogenous
factors lead to mucosal cell damage and destruction [27],
with resulting loss of mucosal integrity. The bowel mucosa
acts as a barrier between the environmental antigens,
including the microbiota, and the host immune system.
After the breakdown of the mucosal barrier function, a
translocation of antigens to the mucosal lamina propria
occurs, leading to the activation of innate and adaptative
immune response [27]. The mechanisms behind the
epithelial cell damage are only partially unveiled, but
several molecules have been found to play a role in this
process: TNFa, a cytokine involved in a myriad of
inflammatory processes, induces intestinal cell apoptosis
[28]; reactive oxidants, such as superoxide and nitric oxide,
induce and amplify mucosal injury [29]; and an excess of
matrix metalloproteinases has been found in ulcerated
bowel lesions [30].
2.2 Mechanisms and Drugs Involved in Mucosal
Healing (MH)
The mechanisms involved in MH are just as complex as for
mucosal injury, and include goblet cell repair to preserve
an intact mucus layer [27], Paneth cell replenishment to
sustain adequate antimicrobial function and allow healing
of the epithelial wound [31], and multiple pathways
resulting in the recruitment of molecules, such as trans-
forming growth factor or intestinal trefoil factors, in order
to close the epithelial gap and reseal the wounded mucosa
[27].
Currently approved drugs for UC may act at one or more
of the different stages of mucosal injury: pre-epithelial
(intestinal mucosal layer, bacteria, alimentary antigens),
epithelial, or post-epithelial (immune response, modulation
of cytokines and growth factors) [27].
Both corticosteroids and aminosalicylates have been
used for decades and are among the most commonly pre-
scribed drugs for UC [3]. The mechanisms through which
they reduce mucosal inflammation include controlling
nuclear factor (NF)-jB expression (a molecule associated
with microscopic tissue abnormalities in IBD) and
inflammatory cytokines (directly modulating cell migration
and proliferation of epithelial cell lines) [32–34]. In addi-
tion, aminosalicylates play a role on the suppression of the
cyclooxygenase-2 gene [35].
Azathioprine and its metabolite 6-mercaptopurine are
thiopurine immunomodulators and act primarily upon the
immune system response by reducing inflammatory infil-
trate in the bowel mucosa, inducing apoptosis and limiting
cell proliferation, consequently arresting the inflammatory
cycle [36].
Calcineurin inhibitors, such as cyclosporin and tacroli-
mus, reduce the TNF-secreting cells in the gut mucosa in
addition to their effects in both T- and B-cell-mediated
immunity [27].
Anti-TNFa drugs, such as infliximab, adalimumab, and
golimumab, act at several steps of mucosal injury,
restricting the inflammatory infiltrate and T-cell prolifera-
tion within the lamina propria [37], and downregulating the
expression of metalloproteinases and proinflammatory
molecules [37]. They also act on the regenerative process,
restoring the protective capabilities of the mucosa by
reinforcing intestinal permeability and mucosal secretion,
activating fibroblasts, and maintaining epithelial regenera-
tion [38].
Vedolizumab is a humanized anti-integrin antibody
selective to its a4b7 heterodimer, and exerts its action in a
rather specific mechanism by limiting both B- and T-cell
lymphocyte fixation on the intestinal vascular endothelial
cells and consequent migration to the lamina propria and
tissue cells [26, 39].
Nevertheless, striking differences in the frequency,
timing, and degree of MH may be found in different UC
patients, even under similar pharmacological approaches,
underlining the importance of several genetic, epigenetic,
environmental and microbiotic factors in this process, a
number of which are probably yet to be uncovered [27].
3 Current Definitions of MH
Endoscopically, active UC may present with various
mucosal abnormalities, the most commonly observed being
erythema, mucosal friability and bleeding, loss of vascular
pattern, erosions, and ulcers [1]. The concept of MH in UC
was first reported more than half a century ago in 1955 by
Truelove and Witts [6], but where the line should be drawn
in order to distinguish endoscopically active disease from
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MH, and which lesions are most important when assessing
UC clinical course and prognosis, remain controversial
topics.
In part, heterogeneity stems from the presence of a large
number of scores, each with its own set of variables, and
several with adaptations and different cut-off points,
resulting in over 20 different definitions of MH just in UC
clinical trials. The endoscopic component of the clinical
Mayo score, introduced in 1987, is currently the most used
score in clinical practice [7]. It includes the variables
erythema, loss of vascular pattern, friability, bleeding,
erosions and ulcers, and ranges from 0 to 3—MH is clas-
sically considered to be a score of 0 (normal mucosa) or 1
(mucosal erythema, decreased vascular pattern, mild fri-
ability) [40]. The Mayo Endoscopic Score (MES) has
several shortcomings, the most important being its low
interobserver agreement [4], which, until now, has pre-
cluded its validation despite its widespread use and con-
tinuous modifications [8].
In 2007, the International Organization for the Study of
Inflammatory Bowel Disease considered MH as the
absence of friability, blood, erosions, and ulcers in all
segments of the bowel mucosa [41], while erythema and
loss of vascular pattern did not preclude the definition of
MH. In line with this, most clinical trials in the anti-TNFa
era adapted the MES by considering any friability as
MES 2 and excluding it from the definition of MH
[8, 42, 43].
However, some authors have recently reported signifi-
cant differences in clinical outcomes, such as clinical
relapse, hospitalization, and surgery rates, between patients
with MES 0 and MES 1 [44–46], while others found a
significant association between MES 0 and a higher like-
lihood of achieving histological healing [19]. The most
recent ECCO guidelines consider endoscopic remission as
MES B1, but complete MH as MES 0 [47].
The Baron score, developed in 1964, is another fre-
quently employed score. In this score, the variable ulcer-
ation is absent and MH is defined as the absense of
friability [48]. This score was further modified and
employed in different configurations in clinical trials
[49, 50] using markedly different cut-offs to categorize
MH, but neither the original score nor the modified ver-
sions have been validated.
Other scores have been developed, such as the Rach-
milewitz Endoscopic Index [51] and the St. Mark’s Index
[52], while some authors simply used isolated endoscopic
findings to distinguish mucosal inflammatory activity from
MH, such as the large Norwegian population-based study
conducted by Froslie et al. [53].
More recently, the Ulcerative Colitis Endoscopic Index
of Severity (UCEIS) was introduced in clinical practice
[54], and including bleeding, vascular pattern, and
erosions/ulcers as variables. This score demonstrated
excellent interobserver agreement [55] and a superior
correlation with clinical outcomes, long-term prognosis,
and mucosal improvement during therapy when compared
with the Mayo score [56], but is only partially validated
[55] and lacks defined cut-offs for severity of endoscopic
disease activity and for MH.
Finally, to date, the Ulcerative Colitis Colonoscopic
Index of Severity (UCCIS) is the only prospectively vali-
dated score [57], demonstrating good correlation with
clinical markers and clinical activity, but it requires the
expert evaluation of six different variables and no defined
MH threshold has been defined. Table 1 summarizes the
different scoring systems for UC, as well as the included
variables and threshold for MH, when applicable.
In order to attenuate the negative influence of low
interobserver agreement exhibited by most endoscopic
scores, a concept of ‘central reading’ gained progressive
relevance, where endoscopic video evaluation is performed
off-site, by one or more experienced central readers
[54, 58, 59]. Additionally, on-site reading may suffer from
biases such as the willingness to include patients even
when inclusion criteria may not be completely met [60].
While further studies are needed to confirm these advan-
tages, promising evidence exists that central reading may
improve adherence to the inclusion criteria [60], as well as
to refine data interpretation, such as the correction of
inadequately high placebo healing rates [61].
4 Achieving MH
4.1 Aminosalicylates
Of all the treatment options currently available for UC, the
most prevalent is undoubtedly mesalamine [3]. Unlike CD,
where aminosalicylates have little effect on clinical activity
and do not induce MH, several authors have demonstrated
their efficacy in achieving both clinical and mucosal
remission in UC patients [62]. In a recent meta-analysis,
including patients with mild to moderate UC, MH was
achieved in 37% of patients taking oral mesalamine and
50.3% of patients taking rectal mesalamine, with no dif-
ferences between formulations (granules vs. tablets or
enemas vs. foam vs. suppositories) or delivery systems
[63]. Other authors found no differences in efficacy
between once, twice or three times daily administration of
mesalamine [3], while a dose-dependent effect of mesala-
mine on MH was demonstrated in the pooled-analysis of
the ASCEND 1 and 2 trials as mesalamine at a dosage of
4.8 g/day was significantly associated with a higher inci-
dence of MH when compared with 2.4 g/day in patients
with mild to moderate UC (80 vs. 68% at week 6;
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p = 0.012) [64]. In an elegantly designed prospective
study by Meucci et al. [43], the combination of oral and
topical mesalamine led to MH (corresponding to an MES
B1) in 67% of patients. The combination therapy has been
shown to improve MH compared with either oral or topical
mesalamine alone in several other trials, with reported
efficacy reaching up to 80% [65, 66]. The long-term effi-
cacy of mesalamine was demonstrated in the recently
published MOMENTUM trial [67] for MMX
Mesalamine, where MH was identified in up to 64% of
patients with clinical response and 76% of those with
clinical remission at 12 months after induction therapy.
4.2 Corticosteroids
In 1955, Truelove and Witts [6] reported that corticos-
teroids were shown to be capable of not only improving
clinical symptoms but also inducing MH—endoscopic
remission was observed in 30% of patients under treatment
versus 10% of those receiving placebo (p = 0.02). Since
Table 1 Ulcerative colitis endoscopic activity scoring systems
Score Variables Score
range
Score for
MH
Validated
Mayo endoscopic score (MES) [29] Erythema 0–3 0–1 or 0b No
Vascular pattern
Friabilitya
Bleeding
Erosions and ulcers
Baron Score [30] Granularity 0–3 0–1c No
Erythema
Vascular pattern
Friability
Bleeding
Erosions and ulcers
Rachmilewitz endoscopic index [33] Granularity 0–12 0–4 No
Vascular pattern
Bleeding
Mucosal damage (erosions, ulcers,
exudate)
St Mark’s Index [34] Friability 0–2 0 No
Exudate
Bleeding
Truelove and Witts [6] Temporal evolutiond 0–3 Not defined No
Ulcerative colitis endoscopic index of severity (UCEIS)
[36]
Vascular pattern 0–8 Not defined Partially
Bleeding
Erosions and ulcers
Ulcerative colitis colonoscopic index of severity
(UCCIS) [39]
Granularity 0–16 Not defined Yes,
prospectivelyVascular pattern
Friability and Bleeding
Erosions and ulcers
Segmental and global assessmente
MH mucosal healing
a In the modified Mayo Score, any friability scores as MES 2
b 0–1 is considered in most clinical trials; recent evidence points towards MES 0 as the most accurate representation of MH
c Any mucosal abnormality, except friability, is considered MH
d This score bases its assessment on comparison with previous observations, and lacks defined endoscopic descriptors
e UCCIS score implies complete observation of the colon, as well as both global and segmental assessment of the entire mucosa in a 4-point
scale of severity
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then, few studies have focused on the relationship between
steroids and MH in UC, until a prospective study by
Ardizzone et al. [49] demonstrated that up to 35% of
patients achieve MH after just one corticosteroid course;
however, long-term results are dismaying. Corticosteroids
are currently considered to be able to induce, but not
maintain, MH in UC patients [3, 40, 49].
Budesonide is a high-potency steroid with low systemic
effects (compared with other steroids, budesonide under-
goes significant first-pass metabolism), with a more
favorable safety profile over systemic steroids. Because
budesonide in its traditional oral formulation has limited
efficacy in the colon [3], its administration has been largely
limited to a foam rectal preparation, with limited efficacy
in both clinical and endoscopic endpoints [3]. Recently,
two strategies to enhance its efficacy have been developed.
First, a Japanese multicenter, prospective study demon-
strated a threefold significant increase in MH for patients
treated with twice the standard dose of budesonide (46.6%
for budenoside 2 mg twice daily vs. 23.6% for 2 mg once
daily; odds ratio [OR] 3.024; p\ 0.001) at week 6 of
treatment [68], although at a cost of increased adverse
events (53.6 vs. 30.9%; p\ 0.05). Second, the develop-
ment of MMX Budesonide, a once-daily 9 mg oral
budesonide with colon delivery formulation, resulted in its
approval for use in mild to moderate UC [69]. A review of
the currently available clinical trials found it to be signif-
icantly superior to placebo at achieving clinical remission
plus MH (17.7 vs. 6.2%, p\ 0.001; OR 3.3, 95% CI
1.7–6.4), but a low incidence of MH should be noted on
both the treatment and placebo arms [70].
4.3 Immunomodulators
While thiopurines in monotherapy have long been associ-
ated with MH in CD [36], data in UC patients were, until
recently, much scarcer. In a prospective, randomized trial,
azathioprine induced MH in 58% of UC patients, compared
with 21% in those receiving mesalamine (OR 5.26, 95% CI
1.59–18.1) [71]. Studies with longer follow-up, up to
2 years, have reported a similar incidence of long-term MH
with azathioprine monotherapy, ranging from 37 to 57%
[53, 72, 73]. In the UC SUCCESS randomized trial [74] for
patients with moderate to severe UC, MH at week 16 was
significantly less frequent when azathioprine was used in
monotherapy (36.8%) than for infliximab monotherapy
(54.5%; p = 0.028) or combination therapy (62.8%;
p\ 0.001). The pharmacokinetic and metabolite pathways
involved in thiopurine mechanism of action and dose-de-
pendent adverse events are complex [75]. Attempts to
improve clinical response and reduce adverse effects in CD
management, using an individualized approach by mea-
suring circulating metabolite levels, have failed to
unequivocally demonstrate an advantage over conventional
weight-based dosage [76]. No such studies have been
undertaken in UC patients.
Few studies exist regarding the use of methotrexate in
UC patients. A Cochrane review failed to demonstrate an
advantage over placebo for the maintenance of endoscopic
or clinical remission in UC [77], while the more recent
METEOR trial, employing higher doses of up to 25 lg/
week in corticosteroid-dependent patients, did not show an
increase in MH for patients receiving methotrexate (35 vs.
25% in the placebo arm; p = 0.28) [78].
Cyclosporin and tacrolimus have been used for corti-
costeroid-refractory acute severe UC. In a randomized
controlled trial, 44% of these patients achieved MH [79].
However, the frequency and severity of adverse effects,
including arterial hypertension, diabetes mellitus, hyper-
kalemia, and infections limit the chronic use of these drugs
and they are often considered as a bridge to other
immunosuppressive drugs, such as thiopurines [80].
4.4 Anti-Tumor Necrosis Factor-a Drugs
To date, anti-TNFa agents (infliximab, adalimumab, or
golimumab) have shown the most robust evidence for effi-
cacy in achieving MH among the approved drugs for UC
[81]. Anti-TNFa drugs are usually reserved for patients with
moderate to severe UC, often steroid refractory, and were
approved following clinical trials performed in this popula-
tion. In a network meta-analysis, anti-TNFa drugs were
significantly more effective than placebo in achieving MH
(relative risk [RR] 0.75, 95% CI 0.66–0.94; p\ 0.01) [81].
In the combined analysis of the ACT1 and ACT2 trials
in moderate to severe UC, 49.9% of patients taking
infliximab achieved MH at week 54, compared with 21%
taking placebo (p\ 0.05). When considering MES 0, 33%
of patients taking infliximab achieved this stricter defini-
tion of MH, more than twice as often as patients taking
placebo (16%, p\ 0.05) [8].
Regarding adalimumab, the ULTRA 1 trial failed to
demonstrate improved efficacy compared with placebo for
achieving MH at week 8 (47 vs. 41%; p = non-significant)
[82]. The ULTRA 2 trial, with a duration of 52 weeks,
included both anti-TNFa-naive and anti-TNFa-experi-
enced patients [83]. Patients taking adalimumab more
frequently achieved MH than those taking placebo, both at
week 8 (41 vs. 32%, p = 0.032) and week 52 (25 vs. 15%,
p = 0.009). However, when stratified by prior anti-TNFa
use, the superiority of adalimumab was only significant for
naive patients (49 vs. 35%, p = 0.014, at week 8; and 31
vs. 19%, p = 0.018, at week 52) [83]. In a combined
analysis of the ULTRA trials, after 4 years of follow-up
more than 25% of patients with moderate to severe UC
treated with adalimumab remained in MH [84].
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The PURSUIT trial enrolled more than 1000 patients
and evaluated the efficacy of golimumab for inducing and
maintaining both clinical remission and MH [85, 86]. In
this trial, golimumab was superior to placebo in achieving
MH, both at the end of induction (44 vs. 29%, p\ 0.002, at
week 6) and following 1 year of maintenance treatment
(42 vs. 27%, p = 0.002) [85, 86].
With regard to combination therapy, combining inflix-
imab with a thiopurine (the UC SUCCESS trial) did not
result in increased rates of MH when compared with
infliximab alone when the endpoint MES\2 was consid-
ered (62.8 vs. 54.6%; p = 0.295), but a post hoc analysis
identified a higher proportion of patients with MES 0 when
combination therapy was used (29.5 vs. 11.7%; p = 0.014)
[74].
Significant emphasis has recently been put on the
pharmacokinetics of anti-TNFa drugs, particularly for their
serum trough levels, as it has shown critical importance in
order to achieve both clinical remission and MH [87, 88].
In fact, trough levels above 3–7 lg/mL for infliximab
[87, 89, 90] and 5–8 lg/mL for adalimumab [88] were
associated with a significantly increased likelihood for
patients to achieve MH (OR 5.60, 95% CI 2.81–11.15
[91]), while an incremental gain in MH depending on anti-
TNFa levels was recently demonstrated in a study by
Ungar et al. [88]. These findings led to the suggestion that
an MH therapeutic window may exist, within which MH is
most likely to be achieved, while values above such a
window will result in toxicity without further clinical
benefit; the exact threshold is yet undetermined, and is
likely to be influenced by individual factors, but highlights
the growing importance of pharmacokinetics and pharma-
codynamics in the management of IBD, as well as the
advantages of a tailored approach to treatment. Finally,
while golimumab serum levels were significantly associ-
ated with clinical response in the PURSUIT trial [85], there
is as yet no published evidence regarding their relation with
MH.
Anti-drug antibodies (ADAs) against anti-TNFa drugs
are one of the most important variables in regulating the
pharmacokinetics of anti-TNFa drugs; all anti-TNFa drugs
have the potential for immunogenicity and ADA formation
[92]. Once formed, ADAs bind anti-TNFa drugs, resulting
in accelerated clearance and reduced half-life being
extensively correlated with loss of clinical response and
inability to achieve MH [89, 93]. An increased risk of ADA
formation exists for patients with previou slow trough
levels of anti-TNFa, episodic administration of anti-TNFa
drugs, and previous ADA formation to another drug in this
class [90, 92]. Current strategies employed to prevent their
formation include increasing the dose and shortening the
intervals of administration [80].
There is ample evidence that adding a thiopurine to an
anti-TNFa drug significantly reduces ADA formation in
CD, and, to a lesser extent, in UC [80], with improved
anti-TNFa clearance and increased trough levels to within
therapeutic range [87, 89, 94]. This reduction in ADA
formation seems particularly beneficial during the first
12 months of anti-TNFa therapy [93], while the choice to
maintain the thiopurine beyond this point should be
weighed against the risks of long-term combination
therapy, namely the increased risk of non-Hodgkin lym-
phoma [3]. Both anti-TNFa drugs and ADA concentra-
tions are dependent on a number of other variables,
including patient sex and body mass [95], albumin and
C-reactive protein serum levels [96],circulating TNFa
[80, 97], and even the severity of mucosal inflammation
[80]. Currently, most evidence regarding ADAs is aimed
at the post-induction treatment phase [88, 93], but earlier
time points, allowing for detection of variability in anti-
TNFa exposure and clearance, together with biomarkers
and clinical assessment, could result in tailored induction
regimens, optimizing both clinical and endoscopic
response and potentially reducing adverse effects and
costs.
4.5 Anti-Integrin Drugs
In the GEMINI trial, patients treated with vedolizumab
achieved MH significantly more frequently than patients
receiving placebo, both at week 6 (40.9 vs. 24.8%;
p\ 0.001) and week 52 (52 vs. 20%; p\ 0.001), respec-
tively [26]. Unfortunately, the few vedolizumab studies
developed since this trial was published were limited to
clinical assessment only, and further evidence is warranted
to consolidate its capacity to induce MH in UC patients.
Table 2 summarizes the characteristics of the most
important trials on the different drugs approved for UC, as
well as their results for achieving MH. Current drugs with
enough evidence for their association with MH in UC are
salicylates, corticosteroids (induction only), calcineurin
inhibitors (induction only) thiopurines, vedolizumab, and
all approved anti-TNFa drugs.
Finally, treatment non-adherence is a key factor in both
clinical response and MH, often overlooked in the clinical
trials setting but recognized as an independent risk factor
for persistent inflammatory activity by several authors [63].
However, a crucial point is the growing evidence
regarding persistent clinical activity in patients where MH
was achieved. Even in patients with partial clinical
response, up to 35% presented with MES 0 during endo-
scopy. This finding highlights the overlap between IBD and
IBS, and the limitations of the symptom-based assessment
of disease activity [67, 98].
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5 Prognostic Relevance of MH
The importance of MH has been known since 1966, when
Wright and Truelove [99] performed serial biopsies on UC
patients and concluded that patients in MH were more
frequently in clinical remission after 1 year (40 vs. 18%).
Since then, a number of authors and clinical trials have
reported on the various outcomes of UC and the influence
of several intervening factors, particularly MH.
In the pre anti-TNFa era, a large population-based study
in Norway identified a reduced 5-year risk of colectomy in
patients achieving MH (2 vs. 7%; RR 0.22, 95% CI
0.06–0.79) [53], independently of the drugs used to this
end. Another study in a group of mild to moderate UC
patients, performed by Meucci et al. [43], demonstrated
that only 23% of patients in clinical remission and MES B1
presented with clinical relapse within 12 months, compared
with 80% of those achieving clinical remission only. The
study by Ardizzone et al., including newly diagnosed UC
patients needing steroids, demonstrated a significant
decrease in both hospitalization (hazard ratio [HR] 3.6,
95% CI 1.56–8.48) and surgery (HR 8.40, 95% CI
1.23–55.19) rates over 5 years for patients within a strin-
gent definition of MH (Baron Score = 0) [49].
In the combined post hoc analysis of the ACT1 and ACT2
trials, MH after the infliximab induction phase (week 8) was
significantly associated with long-term corticosteroid-free
remission (p\ 0.001) and a decreased risk of colectomy (5
vs. 15%; p\ 0.001) at both week 30 and week 54. Addi-
tionally, up to 77% of patients in MH at week 8 were still in
MH at week 54 [8]. Similarly, a prospective Italian study
showed that patients in MH at 3 months of treatment for
moderate to severe UC had less clinical relapse at 15 months
(27.5 vs. 73.9%) [100], while a French multicenter study
found striking differences in long-term colectomy rates
between patients with MH (3%) and without MH (39%). In
multivariate analysis, MH was indeed the only variable
associated with colectomy-free survival (OR 18.01, 95%
CI 1.58–204.92). Interestingly, the authors also demon-
strated a significantly higher risk of cumulative infliximab
failure for up to 4 years after treatment initiation if MH
was not present at the index endoscopic evaluation (OR
3.23, 95% CI 1.48–7.0), suggesting that MH could play an
important protective role against secondary anti-TNFa
failure.
A common concern in patients with longstanding UC is
the increased risk of dysplasia and colorectal cancer, which
is thought to be consequential to persistent colonic
inflammation [47]. Several authors have reported on an
increased risk of dysplasia and progression to colorectal
cancer in patients with endoscopically active disease when
compared with those presenting with MH [101, 102], while
others have demonstrated a normalization of the risk to that
of a health individual when complete MH was achieved
[103]. In a 2005 meta-analysis, the use of mesalamine was
further associated with a significant decrease in the risk of
colorectal cancer (OR 0.51, 95% CI 0.37–0.69) [104], but
whether this improved outcome is solely related to the
decrease in epithelial inflammation or complemented by
anticarcinogenic properties of the drug has not yet been
elucidated.
It should be noted that all drug clinical trials to date used
a broader definition of MH, including patients with mild
erythema or loss of vascular pattern (corresponding to
modified MES 1). This option resulted in striking differ-
ences when evaluating drug efficacy. For instance, if the
ASCEND trial results were adapted to exclude MES 1, and
consider MH as MES 0, only 32% of patients taking
mesalamine 4.8 g/day would be in MH, not 80% as was
reported in the trial [64]. Because of competing commer-
cial interests, new drugs tend to use the same endpoints as
those previously used, easing comparison and underscoring
improved results.
5.1 Mayo Endoscopic Score (MES) 0 Versus MES 1
Recently, various authors have reported on different out-
comes in patients with MES 0 (no mucosal abnormalities)
and MES 1 (mild erythema or decreased vascular pattern),
while others now strictly define MH as an endoscopically
normal mucosa.
In the subgroup analysis of the ACT1 and 2 trials,
patients with MES 0 were significantly more often in
corticosteroid-free remission after 1 year of follow-up than
patients with MES 1 (73 vs. 47%; p\ 0.001), while no
differences were found in the colectomy rate [8]. Two
Japanese studies with a 5-year follow-up (Yokoyama et al.
[105] and Nakarai et al. [46]) were also among the earliest
to report on different outcomes for complete MH. The
former demonstrated a correlation between MES at base-
line and risk of clinical relapse during follow-up, and a
significant difference in sustained remission between
MES 0 (78%) and MES 1 (40%; p\ 0.001). Similarly, the
latter found patients with MES 1 presented with an
increased risk of clinical relapse when compared with
MES 0 (HR 8.17, 95% CI 4.19–17.96), but also an
increased risk of hospitalization (HR 10.48, 95% CI
1.90–195.22) [46]. Again, neither study demonstrated a
difference in colectomy rates, suggesting perhaps that
while MES 1 is associated with adverse outcomes, such
inflammation is probably not as severe as to increase the
risk of colectomy or to increase it in a tenuous manner.
Adequately powered trials may be needed to enlighten this
subject.
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A prospective study by Barreiro-de Acosta et al., includ-
ing patients in clinical remissionwith eitherMES 1 orMES 0
during endoscopy studies, reported a relapse rate of 26.2%
after 12 months of follow-up [45]. The risk of relapse was
significantly higher in patients with MES 1 (41.0 vs. 19.3%;
p\ 0.01), as confirmed in a Kaplan–Meier survival analysis
(Chi-square 13.46; p\ 0.001). This effect was indepen-
dently significant for all three extents of disease. The latest
evidence towards the significance of complete MH comes
from a Portuguese study [44] in which patients with MES 1
were at increased risk of relapse during follow-up (27.3 vs.
11.5%; p = 0.022) and adverse outcomes, including the
need for corticosteroids and hospitalization (13.0 vs. 3.3%;
p = 0.044). In the subgroup analysis of disease extent,
patients with left-sided and extensive colitis and MES 1
were at increased risk of relapse, but not in cases of proctitis.
In both studies, MES 0was the only variable associated with
clinical relapse in multivariate analysis (OR 6.27, 95% CI
2.73–14.40, and OR 2.89, 95% CI 1.14–7.39, respectively
[44, 45]). While previous studies showed no differences in
colectomy rates between MES 0 and MES 1, these recent
works report no colectomy at all, reflecting a progressive
paradigm shift in UC as the treat-to-target approach towards
MH in UC patients becomes the norm, and more severe
consequences of the disease tend to be seldom observed. The
summarized findings of these studies comparing the out-
comes between MES 0 and MES 1 are included in Table 3.
6 Current and Future Perspectives
6.1 Advanced Endoscopic Imaging
As the tide turns and more clinicians turn their aims
towards complete MH, the knowledge and technology
advances towards more accurate and detailed observation
during endoscopy. Recently, advanced imaging techniques,
such as high-definition colonoscopy, magnifying endo-
scopy, and virtual chromoendoscopy, have been suggested
as a complement to white-light colonoscopy. Virtual
chromoendoscopy has resulted in a significant increase in
characterization of both severity and extent of mucosal
inflammation in UC patients (p\ 0.001), with no increase
in procedure duration in a randomized controlled trial
[106], and, in a multicenter study, was not only more
sensitive than white light in the detection of mild endo-
scopic changes but also correlated more accurately with
histological activity [107].
6.2 Histological Healing
Histological healing has long been reported as an important
endpoint for UC patients, and some authors are now
suggesting that histology could combine with endoscopy,
or even supersede it, as the most adequate method for
assessment of MH in UC patients.
As early as 1991, histological activity has been associ-
ated with an increased risk of relapse at 12 months, when
Riley et al., in a study of 82 patients, found significantly
higher disease relapse rates for UC patients with either of
the following histological markers: acute inflammatory cell
infiltrate, crypt abscesses, mucin depletion, and breaches in
the surface epithelium [108]. More recently, histological
healing was additionally associated with a reduced risk of
hospitalization and colectomy [109, 110] for as long as
6 years of follow-up [24]. Basal plasmocytosis, in partic-
ular, was identified as a marker of histological activity,
present in up to 21% of patients despite MH [4], and sig-
nificantly associated with an increased risk of disease
relapse [22]. Later, the development of the Geboes score
and the Riley score have allowed objective measurement of
histological activity, and both demonstrate excellent
interobserver agreement [18, 111]. Many other scoring
systems followed, and as many as 20 have been described
to date [25, 112, 113], including the recently validated
Robarts histopathology index [112] and the Nancy score
[113].
There is some evidence that significant histological
activity may be present in up to 24–40% of UC patients
with endoscopic findings compatible with MH
[19, 22, 24, 110]. However, it should be noted that com-
plete MH (MES 0) was significantly associated with a
lower incidence of histological activity when compared
with MES 1 (7 vs. 52%; p\ 0.001) [19], and was reported
to accurately reflect normal histology on biopsies [13, 114].
Currently, the use of histological healing as an endpoint
is hindered by the absence of prospective studies evaluat-
ing the impact of current drugs, particularly anti-TNFa
agents, in the process of histological healing, as well as by
insufficient data regarding long-term outcomes such as
disease progression, hospitalization, and surgery [21, 41].
7 Conclusions
UC is a chronic inflammatory disease with severe conse-
quences, including the need for hospitalization and colec-
tomy and the increased long-term risk of colorectal cancer.
Most of the currently approved drugs for UC, including
the widely employed aminosalicylates, thiopurines such as
azathioprine, vedolizumab and, in particular anti-TNFa
drugs, have shown to be able to achieve and maintain MH
in a large number of patients, and significantly more often
than placebo.
MH has been significantly associated with improved
outcomes in UC patients, and established itself as a
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crucial endpoint in the management of the disease in
both retrospective and prospective studies. Nevertheless,
while clinical practice is currently adapting to the
available evidence, and switching from a symptom-
based approach towards endoscopic-based management,
so too is the definition of mucosa healing in constant
adjustment.
Recent evidence has shed light on the importance of not
just partial but complete MH as a preferred goal while
planning patient treatment. Histological healing may one
day be the ultimate endpoint for UC. For achieving these
ambitious goals, a perfect interaction is needed between
increasingly accurate endoscopic, and even histological,
assessment of the disease and prompt and adequate
Table 3 Studies comparing outcomes between MES 1 and MES 0
Authors Country, year of
publication
Patients
(n)
Follow-
up
Main results
Colombel et al. [8] International
Multicenter, 2011
147a 12
months
Significantly higher clinical relapse in patients with MES 1 compared with
MES 0
73 vs. 47%; p\ 0.001
No differences in colectomy rates between MES 0 and MES 1
5 vs. 5%; p = NS
Yokoyama et al.
[105]
Japan, 2013 38 5 years Significantly higher clinical relapse in patients with MES 1 compared with
MES 0
60 vs. 22%; p\ 0.001
No differences in colectomy rates between MES 0 and MES 1
Data not shown
Nakarai et al. [46] Japan, 2014 183 5 years Significantly higher clinical relapse in patients with MES 1 compared with
MES 0
HR 8.17, 95% CI 4.19–17.96; p\ 0.001
Increased risk of hospitalization in patients with MES 1
HR 10.48, 95% CI 1.90–195.22; p = 0.0044
No differences in colectomy rates between MES 0 and MES 1
Data not shown
Barreiro-de-
Acosta et al. [45]
Spain, 2015 187 12
months
Significantly higher clinical relapse in patients with MES 1 compared with
MES 0
41.0 vs. 19.3%; p\ 0.01
In the subgroup analysis, MES 1 was associated with increased relapse in the
three extents of the disease:
Proctitis—25 vs. 5%; p = 0.04
Left-sided colitis—48 vs. 14%; p\ 0.01
Extensive colitis—38 vs. 7%; p\ 0.02
No colectomy during follow-up
Boal Carvalho
et al. [44]
Portugal, 2015 138 12
months
Significantly higher clinical relapse in patients with MES 1 compared with
MES 0
27.3 vs. 11.5%; p = 0.022
In the subgroup analysis, MES 1 was associated with increased relapse in left-
sided and extensive colitis, but not proctitis
Proctitis—25 vs. 12%; p = NS
Left-sided/extensive colitis—29.7 vs. 11.1%; p = 0.049
Increased risk of hospitalization/need for corticosteroids in patients with
MES 1
13.0 vs. 3.3%; p = 0.044
No colectomy during follow-up
MES Mayo Endoscopic Score, HR hazard ratio, NS non-significant, CI confidence interval
a Total number of patients in the ACT1 and 2 trials = 728; only 147 were included in the subanalysis of patients with MES 0 or MES 1 at
week 8
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treatment with effective drugs, capable not only of con-
trolling the symptoms but muting the inflammation itself.
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